Details of the Drug Combination

General Information of Drug Combination (ID: DCIOVOY)

Drug Combination Name

LY03004 Acarbose

Indication

Disease Entry	Status	REF
Chronic myelogenous leukemia	Investigative	[1]

Component Drugs

LY03004 DME5TUR

Acarbose DMRM3AW

N.A.

Small molecular drug

High-throughput Screening Result

Testing Cell Line: KBM-7

Zero Interaction Potency (ZIP) Score: 24.16

Bliss Independence Score: 24.16

Loewe Additivity Score: 38.65

LHighest Single Agent (HSA) Score: 38.67

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of LY03004

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Phase 3	[2]

Indication(s) of Acarbose

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Approved	[3]
Non-insulin dependent diabetes	5A11	Approved	[4]
Cardiovascular disease	BA00-BE2Z	Phase 3	[3]

Acarbose Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Intestinal maltase-glucoamylase (MGAM)	TTXWASR	MGA_HUMAN	Modulator	[5]
------------------------------------------------------------------------------------

References

1	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6791).
4	Acarbose FDA Label
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.